Get the Stockscreener App
36.27
4.28%
1.49
After Hours:
36.25
-0.02
-0.06%
Cogent Biosciences Inc stock is traded at $36.27, with a volume of 3.43M.
It is up +4.28% in the last 24 hours and down -6.45% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$34.78
Open:
$35.22
24h Volume:
3.43M
Relative Volume:
1.07
Market Cap:
$5.57B
Revenue:
-
Net Income/Loss:
$-284.08M
P/E Ratio:
-14.97
EPS:
-2.4234
Net Cash Flow:
$-234.65M
1W Performance:
+2.11%
1M Performance:
-6.45%
6M Performance:
+287.91%
1Y Performance:
+339.64%
1-Day Range:
$34.50
$37.00
1-Week Range:
$32.93
$37.00
52-Week Range:
$3.72
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
36.27 | 5.34B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-10-25 | Upgrade | Stifel | Hold → Buy |
| Nov-10-25 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-16-25 | Initiated | Stifel | Hold |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
Cogent Biosciences announces presentation at the 44th annual J.P. Morgan Healthcare conference - MarketScreener
Cogent Biosciences, Inc. CEO Andrew Robbins to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
COGT Gets a Boost: HC Wainwright & Co. Raises Target Price | COGT Stock News - GuruFocus
Liquidity Mapping Around (COGT) Price Events - Stock Traders Daily
Cogent Biosciences down after market close on insider sales - MSN
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Best Biotech Stocks To Follow TodayDecember 31st - MarketBeat
Cogent Biosciences Chief Scientific Officer John Robinson Sells 50% Of Holding - simplywall.st
EV Market: Will Cogent Biosciences Inc stock see PE expansionJuly 2025 News Drivers & Capital Efficiency Focused Ideas - moha.gov.vn
Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day. - Barron's
Cogent Biosciences Stock Jumps in 2025 as Executives Sell Shares - Barron's
Cogent Biosciences, Inc. (COGT) Stock Analysis: Potential 38% Upside as Analysts Show Strong Buy Interest - DirectorsTalk Interviews
When Will Cogent Biosciences, Inc. (NASDAQ:COGT) Become Profitable? - 富途牛牛
Voya Investment Management LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing - ts2.tech
Cogent Biosciences (NASDAQ:COGT) Shares Gap Down Following Insider Selling - MarketBeat
Cogent Biosciences Stock Pre-Market (-4.4%): Insider Selling Overwhelms Positive NDA News - Trefis
Wave of High-Level Insider Sales Rocks Cogent Biosciences - TipRanks
Cogent Biosciences presents full SUMMIT results of bezuclastinib - MSN
Cogent Biosciences (COGT) Shares Drop Following Insider Sales - GuruFocus
Cogent Biosciences stock falls after multiple insider sales By Investing.com - Investing.com UK
Cogent Biosciences stock falls after multiple insider sales - Investing.com
Cogent Biosciences (NASDAQ:COGT) Insider Sells $3,198,245.40 in Stock - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Insider John Edward Robinson Sells 90,000 Shares - MarketBeat
Insider Sell: Jessica Sachs Sells 82,642 Shares of Cogent Biosci - GuruFocus
Cogent Biosciences Insider Sold Shares Worth $3,486,600, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences Insider Sold Shares Worth $3,198,245, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences Insider Sold Shares Worth $2,978,360, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences Insider Sold Shares Worth $2,515,500, According to a Recent SEC Filing - MarketScreener
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis - The Globe and Mail
Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib - ts2.tech
Cogent Biosciences Submits New Drug Application for Bezuclastinib for Non-Advanced Systemic Mastocytosis - marketscreener.com
Cogent Biosciences (COGT) Advances Bezuclastinib with FDA Submis - GuruFocus
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update - Insider Monkey
Cogent Biosciences jumps after strong late-stage results in advanced systemic mastocytosis - MSN
Certain Stock Options of Cogent Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 27-DEC-2025. - MarketScreener
Price-Driven Insight from (COGT) for Rule-Based Strategy - Stock Traders Daily
Squarepoint Ops LLC Purchases Shares of 101,518 Cogent Biosciences, Inc. $COGT - MarketBeat
What analysts say about Cogent Biosciences Inc stockMarket Sentiment Surveys & Avoid Market Traps With Pro-Level Warnings - earlytimes.in
Cogent Biosciences Earnings Notes - Trefis
Cogent Biosciences Inc (COGT) Bonds - GuruFocus
Assenagon Asset Management S.A. Purchases 380,345 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
What hedge fund activity signals for Cogent Biosciences Inc. stockJuly 2025 Gainers & Real-Time Buy Signal Notifications - Улправда
Why Cogent Biosciences Inc. stock is rated strong buyJuly 2025 Retail & Fast Gain Stock Trading Tips - ulpravda.ru
Will Cogent Biosciences Inc. stock outperform Nasdaq indexJuly 2025 News Drivers & AI Powered Buy/Sell Recommendations - Улправда
Wall Street Zen Upgrades Cogent Biosciences (NASDAQ:COGT) to Hold - MarketBeat
Officer Pinnow Acquires 119,200 Of Cogent Biosciences Inc [COGT] - TradingView — Track All Markets
How Cogent Biosciences Inc. stock performs in stagflation2025 Market Sentiment & Smart Allocation Stock Tips - Улправда
Cogent Biosciences (COGT): JP Morgan Raises Price Target to $67 - GuruFocus
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):